RxDoctor Payments Data

Jeffrey Heebner

Family Medicine · Conshohocken, PANPI 1699712968

Payments from drug & device makers

$332in general payments, 2019–2025

Across 19 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$151
  • Amarin Pharma, Inc.$35
  • Electronic Waveform Lab, Inc.$30
  • Shire North American Group Inc$23
  • Pfizer$23
  • Johnson & Johnson$21
  • plus $49 from 4 others

What the payments were for

  • Food & beverage$332100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)9$151
Amarin Pharma, Inc.2$35
Electronic Waveform Lab, Inc.1$30
Shire North American Group Inc1$23
Pfizer1$23
Johnson & Johnson1$21
Novo Nordisk1$13
Amgen1$13
Teva Pharmaceuticals USA, Inc.1$12
Lilly USA, LLC1$11

How this compares

$332 in reported general payments places this provider in the 50th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$221,700
Medicare patients
238
Services billed
1,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban336$165,280
TrulicityDulaglutide91$102,918
AtivanLorazepam13$39,434
XareltoRivaroxaban55$34,675
JardianceEmpagliflozin53$26,637
LinzessLinaclotide38$22,320
TrintellixVortioxetine Hydrobromide60$21,768
MyrbetriqMirabegron58$19,621
NuedextaDextromethorphan Hbr/Quinidine25$19,455
GemtesaVibegron42$18,081
FarxigaDapagliflozin Propanediol30$14,767
CreonLipase/Protease/Amylase17$14,562
JanuviaSitagliptin Phosphate18$13,120
Potassium Chloride297$11,614
Rosuvastatin Calcium236$9,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$23$172,753362 claims
Lilly USA, LLCTrulicity$11$102,91891 claims
AbbVieLinzess, Creon, Lumigan, Synthroid$151$44,595112 claims
Johnson & JohnsonXarelto$21$34,67555 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Conshohocken

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →